Cargando…
PTCH1 mutation promotes antitumor immunity and the response to immune checkpoint inhibitors in colorectal cancer patients
Immunotherapy has emerged as an effective therapeutic strategy for various cancers, including colorectal cancer (CRC), but only a subset of MSI-H patients can benefit from such therapy. Patched1 (PTCH1) is a frequently altered gene in CRCs and its mutations contribute to unregulated Hedgehog (Hh) si...
Autores principales: | Wang, Yanni, Chen, Huan, Jiao, Xi, Wu, Lihong, Yang, Ying, Zhang, Jiao, Wu, Lijia, Liu, Chang, Zhuo, Na, Li, Shuang, Gong, Jifang, Li, Jian, Zhang, Xiaotian, Wang, Xicheng, Peng, Zhi, Qi, Changsong, Wang, Zhenghang, Li, Jie, Li, Yan, Lu, Zhihao, Zhang, Henghui, Shen, Lin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8738454/ https://www.ncbi.nlm.nih.gov/pubmed/34028566 http://dx.doi.org/10.1007/s00262-021-02966-9 |
Ejemplares similares
-
Alterations in DNA damage response and repair genes as potential biomarkers for immune checkpoint blockade in gastrointestinal cancer
por: Wang, Yujiao, et al.
Publicado: (2022) -
Prediction of immune checkpoint inhibition with immune oncology-related gene expression in gastrointestinal cancer using a machine learning classifier
por: Lu, Zhihao, et al.
Publicado: (2020) -
Serological biomarkers predict immune-related adverse events and clinical benefit in patients with advanced gastrointestinal cancers
por: Wang, Yanni, et al.
Publicado: (2022) -
Tumor copy-number alterations predict response to immune-checkpoint-blockade in gastrointestinal cancer
por: Lu, Zhihao, et al.
Publicado: (2020) -
Germline HLA-B evolutionary divergence influences the efficacy of immune checkpoint blockade therapy in gastrointestinal cancer
por: Lu, Zhihao, et al.
Publicado: (2021)